Biologix Hair Inc. Voluntarily Suspends SEC Reporting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biologix Hair Inc. Voluntarily Suspends SEC Reporting Obligations

TORONTO, ONTARIO--(Marketwired - Aug. 2, 2013) - Biologix Hair Inc. (OTCBB:BLGX) (OTCQB:BLGX) announced that it filed a Form 15 as notice of suspension of the duty to file periodic reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934 with the Securities and Exchange Commission ("SEC") August 1, 2013. The Company is thereby voluntarily suspending its reporting obligations under the Securities Exchange Act of 1934.

As a result of filing Form 15, Biologix will no longer be required to file annual and quarterly reports with the SEC. The Company took this action in order to maximize management efficiency and cost effectiveness during its fast-paced development stage. The Company also aims to benefit from new capital-raising exemptions contained in the JOBS Act, which will allow registration exempt companies to raise up to $50 million in any 12-month period from accredited investors.

The Company's common stock will continue to be eligible for quotation on the OTC Pink ( www.otcmarkets.com ) quotation system, but will cease to be quoted or traded on the OTC Bulletin Board. The change in trading venue is to become effective shortly after the filing but Biologix will suspend all periodic report filing with the SEC effective immediately.

"Our Directors unanimously supported the voluntary suspension of filings after careful consideration of our short- and long-term goals, and with a view to maximizing shareholder value," said Biologix Chairman Ron Holland. "We expect that the added flexibility and cost effectiveness associated with a temporary 'dark period' will quicken our pace during the development stage and expand our strategic options in terms of financing and development of our intellectual property. In light of JOBS Act reforms, we strongly believe that the benefits of going dark clearly outweigh the benefits we received from maintaining our OTCBB quotation."

The Company plans to provide timely quarterly and annual reports pertaining to its financial performance and other announcements on its website. The Company also intends to resume its SEC reporting obligations under the Securities Exchange Act of 1934 once the timing is optimal for the continuous success of its business operations.

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and late 2011, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.

BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.

Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 147 countries have as of now contracted, including Canada and the United States.

Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™ and is rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.

Although the Biologix Hair Therapy System™ is currently not able to be offered in more heavily regulated markets, such as the United States, Canada and the European Union, there are countries and regions with less restrictive regulatory barriers that enable Biologix to provide immediate treatment via its clinician network while simultaneously focusing on obtaining regulatory approvals for all markets, worldwide.

BHS is in the process of opening a prototype commercial hair therapy treatment and medical training center in Cartagena, Colombia. The fee-for-service clinic is expected to be operational before the end of October 2013. Additionally, management is currently working together with its Medical Advisory Board and its team of legal advisors to determine in which strategic locations around the world to begin offering commercial treatment options - expected to be available in the first quarter of 2014.

To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.

Disclaimer

This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.

Biologix Hair Inc. Corporate Communications +1 647.494.8001 Toll Free: +1 855.292.8585 CorporateCommunications@BiologixHair.com www.BiologixHair.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 202

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 0

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 39

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 77

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Settles SEC Investigation While Strengthening Operations

Updated Category News Views 215

BD Reaches Settlement with the SEC BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has announced a significant agreement to resolve an investigation by the U.S. Securities and Exchange Commission (SEC). This follows concerns regarding prior public disclosures related to the BD Alaris™ System. Key Details of the Resolution The...

Continue Reading
Seizing the Managed Detection and Response Market Opportunity

Updated Category News Views 232

Unlocking the Managed Detection and Response Market Potential Middleton, Massachusetts – QKS Group, a leading market intelligence and advisory firm, recently released an insightful report on the global Managed Detection and Response (MDR) Market. This comprehensive analysis targets industry leaders eager to tap into a rapidly growing sector. According to their findings,...

Continue Reading
Expanding Horizons: Coldwell Banker's Venture into Africa

Updated Category News Views 94

Coldwell Banker Real Estate's New Milestone Coldwell Banker Tanzania and Zanzibar have officially joined the growing network of Coldwell Banker Real Estate LLC, marking an exciting expansion into Africa. This new master franchise embodies the brand’s ongoing commitment to deliver top-tier real estate services on an international scale. Seizing Growing Markets The real...

Continue Reading
Automotive Grade Linux Unveils SoDeV Platform for Advancements

Updated Category News Views 289

Automotive Grade Linux Introduces SoDeV for Software Defined Vehicles In an exciting development for the automotive industry, Automotive Grade Linux (AGL) has launched SoDeV, an open-source reference platform aimed at significantly enhancing the development of Software Defined Vehicles (SDVs). This innovative platform allows developers to focus on software-first...

Continue Reading
Exploring Promising Tech Stocks Ahead of Future Opportunities

Updated Category News Views 257

Opportunity in Oversold Tech Stocks The information technology sector is witnessing a notable shift, with several stocks currently considered undervalued. These oversold stocks represent potential opportunities for savvy investors looking to capitalize on future growth. By focusing on these stocks, investors can identify undervalued companies that have the potential for...

Continue Reading